Download presentation
Presentation is loading. Please wait.
1
PAST, PRESENT AND FUTURE
MarkPap Technology PAST, PRESENT AND FUTURE BioSciCon, 2007
2
BioSciCon, Inc. BioSciCon is a women-owned small business company that has developed and has rights to manufacture, market and sale patented biomarker-based MarkPap® technology products intended for cytological early detection of cervical cancer/pre-cancer. MarkPap technology is more accurate, faster and less costly than current Pap test technologies. December 9, 2018 Business Overview 2007
3
MarkPap® technology: Biomarker makes a difference
MarkPap biomarker is cytoplasmic expression of genetic changes in cervical cells during transformation from normal to pre-malignant (dysplastic) and malignant, with or w/o HPV infection. When visualized with MarkPap test biomarker appears as a red pigment flagging only abnormal cells. December 9, 2018 Business Overview 2007
4
MarkPap test applied in Pap test as a new ancillary method
Abnormal specimen, ASC-H. Three small abnormal (red) cells among several normal cells. Screening magnification (left). Diagnostic magnifications (right). Abnormal cells cannot be missed! December 9, 2018 Business Overview 2007
5
Biomarker is positive in cancer and HPV induced abnormal cells
MarkPap smear from a patient with invasive cervical carcinoma HPV positive. Red biomarker is positive in all abnormal cells where micro-vacuolization and dysplastic features are present together December 9, 2018 Business Overview 2007
6
MarkPap screening and HPV vaccines
Cervical cancer was the major killer of women with malignant diseases. Measures for prevention and control, such as mass screening with low-cost and accurate methods such as MarkPap, with added benefit of HPV vaccines, raise hopes for cervical cancer eradication in the years to come. December 9, 2018 Business Overview 2007
7
CLINICAL TRIALS RESULTS
2,000 s/s NEW CTR-1 Pap CTR-2 LBP Advantage Ancillary CAP Pap ThP CAP+PAP MarkPap D-Ac, Se, FN Diagnostic Accuracy* 0.93 0.51 0.82 1.8:1:1.6 Sensitivity 0.88 0.8 1.7:1:1.5 False negative 4 18 17 1:5:4 December 9, 2018 Business Overview 2007
8
Intellectual Property Market protection
MarkPap is currently protected: 1. Parent patent US PTO # 6,143,512 Granted November 2000 2. Patent pending 3. International Application (PCT 2004) 4. Trademark MarkPap® Continuing developments: 5. Digital MarkPap (TelePap) 6. MarkPap for home self-testing (HomePap) December 9, 2018 Business Overview 2007
9
Competitive MarkPap® advantages on the market
Better accuracy for lower cost Better productivity for less liability Mass cervical cancer screening worldwide with HomePap and TelePap Huge societal benefit saving women’s lives with enormous market and incredible potential for profit . December 9, 2018 Business Overview 2007
10
Market Opportunity – WORLD 1.7 billion women at risk
Developing countries 1,400 M women at risk 100 M test per year Outreach 6.5% China 300 M women at risk 72 M test and growing Outreach 24% US & EU 250 M women at risk 95 M tests annually 3-5 B dollars market Outreach: ~80% at 3 years US/EU 250M Risk China 300M Risk Developing Countries 1.4 Billion Women at Risk December 9, 2018 Business Overview 2007
11
Returns to investors Negotiable terms for investment:
Percent of profit on sales of the product (royalty) Percent interest in the MarkPap LLC (equity investment) Interest on investment BioSciCon offers all options to investors. December 9, 2018 Business Overview 2007
12
MarkPap technology in the next decade
Towards this vision, we are developing a palette of products which are unique because they are based on the proprietary biomarker. They include new types of specimen collection (MarkPap Self), digital imaging for fast, reliable and low-cost diagnosis at distance (MarkPap Digital) and automation for specimen processing, reading and interpretation (MarkPap Auto). New products as MarkPap Cervical Cell Bank are envision to provide material for further basic research and new drug development December 9, 2018 Business Overview 2007
13
BioSciCon in the next decade
BioSciCon ultimate goal is the HomeTelePap test for global cervical cancer screening, monitoring of the effects of HPV vaccination and saving thousands of women’s lives. The business arm MarkPap LLC to manufacture, market, distribute and sale MarkPap technology products Independent non-profit corporation to collect and organize past, present and future BioSciCon activities for the advancement of education and science on women’s health. December 9, 2018 Business Overview 2007
14
Acknowledgement The National Institutes of Health
NIH SBIR Program (1R43CA , 1R43CA , 2R44CA ) NIH Commercialization Assistance Program Larta Institute, San Francisco, CA December 9, 2018 Business Overview 2007
15
BioSciCon, Inc. MarkPap, LLC Web site: www.bioscicon.com
14905 Forest Landing Circle Rockville, MD 20850 Shady Grove Development Park, Gaithersburg, MD 20877 Frederick Innovation Technology Center, Frederick, MD 21701 TeL: Fax: Web site: December 9, 2018 Business Overview 2007
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.